What is Wedbush's Forecast for TVTX FY2025 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at Wedbush dropped their FY2025 EPS estimates for Travere Therapeutics in a research report issued to clients and investors on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.74) for the year, down from their prior estimate of ($0.69). Wedbush has a "Outperform" rating and a $30.00 price objective on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics' Q4 2025 earnings at ($0.08) EPS and Q1 2026 earnings at ($0.05) EPS.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.08. The business had revenue of $81.73 million for the quarter, compared to analysts' expectations of $77.44 million. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The firm's revenue was up 83.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.76) EPS.

TVTX has been the topic of several other reports. Guggenheim restated a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. Scotiabank reaffirmed an "outperform" rating on shares of Travere Therapeutics in a report on Friday, April 11th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Travere Therapeutics in a report on Tuesday, July 1st. Stifel Nicolaus lifted their target price on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a report on Wednesday, April 23rd. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $32.14.

Travere Therapeutics Stock Down 2.4%

TVTX stock traded down $0.40 during midday trading on Thursday, hitting $16.11. The company's stock had a trading volume of 1,443,829 shares, compared to its average volume of 1,618,276. The company has a debt-to-equity ratio of 9.46, a current ratio of 2.05 and a quick ratio of 2.03. Travere Therapeutics has a twelve month low of $7.93 and a twelve month high of $25.29. The company's fifty day moving average price is $15.87 and its 200 day moving average price is $18.06. The stock has a market capitalization of $1.43 billion, a P/E ratio of -5.73 and a beta of 0.72.

Insider Transactions at Travere Therapeutics

In related news, insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the transaction, the insider directly owned 128,215 shares of the company's stock, valued at $2,698,925.75. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher R. Cline sold 1,784 shares of Travere Therapeutics stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the transaction, the chief financial officer directly owned 93,126 shares in the company, valued at approximately $1,960,302.30. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,294 shares of company stock worth $485,123 over the last quarter. Corporate insiders own 4.06% of the company's stock.

Institutional Trading of Travere Therapeutics

A number of hedge funds have recently modified their holdings of TVTX. GF Fund Management CO. LTD. bought a new position in shares of Travere Therapeutics in the 4th quarter worth approximately $31,000. Sterling Capital Management LLC raised its stake in Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after acquiring an additional 2,115 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Travere Therapeutics during the 1st quarter worth approximately $62,000. Gen Wealth Partners Inc bought a new stake in Travere Therapeutics during the 4th quarter worth approximately $73,000. Finally, KBC Group NV bought a new stake in Travere Therapeutics during the 1st quarter worth approximately $75,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.